Literature DB >> 17283257

C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice.

Wanpen Vongpatanasin1, Gail D Thomas, Randall Schwartz, Lisa A Cassis, Sherri Osborne-Lawrence, Lisa Hahner, Linda L Gibson, Steven Black, David Samols, Philip W Shaul.   

Abstract

BACKGROUND: Chronic elevations in circulating C-reactive protein (CRP) are associated with a greater risk of hypertension. Whether elevations in CRP cause hypertension is unknown. METHODS AND
RESULTS: Chronic, conscious blood pressure (BP) measurements were performed by radiotelemetry in wild-type CF1 control and CF1 transgenic mice expressing rabbit CRP (CF1-CRP) under the regulation of the phosphoenolpyruvate carboxykinase promoter. Compared with controls, CF1-CRP mice had hypertension that was predominantly systolic, and the severity of hypertension varied in parallel with changes in CRP levels modulated by dietary manipulation. Mice that were hemizygous for the transgene with CRP levels of 9 microg/mL were also hypertensive, indicating that modest elevations in CRP are sufficient to alter BP. CRP transgenic mice had exaggerated BP elevation in response to angiotensin II and a reduction in vascular angiotensin receptor subtype 2 (AT2) expression. In contrast, the decline in BP with angiotensin receptor subtype 1 (AT1) antagonism and vascular AT1 abundance were unaltered, which indicates a selective effect of CRP on AT2. Ex vivo experiments further showed that the CRP-induced decrease in AT2 is a direct effect on the vascular wall, not requiring systemic responses, and that it is reversed by an NO donor, which indicates a role for NO deficiency in the process. In parallel, the chronic inhibition of NO synthase in wild-type mice attenuated vascular AT2 expression without affecting AT1.
CONCLUSIONS: These findings provide direct evidence for CRP-induced hypertension, and they further identify a novel underlying mechanism involving downregulation of AT2 related to NO deficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283257     DOI: 10.1161/CIRCULATIONAHA.106.664854

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

Review 1.  Cardiovascular consequences of obese and nonobese obstructive sleep apnea.

Authors:  Kannan Ramar; Sean M Caples
Journal:  Med Clin North Am       Date:  2010-05       Impact factor: 5.456

2.  IgG receptor FcγRIIB plays a key role in obesity-induced hypertension.

Authors:  Nathan C Sundgren; Wanpen Vongpatanasin; Brigid-Meghan D Boggan; Keiji Tanigaki; Ivan S Yuhanna; Ken L Chambliss; Chieko Mineo; Philip W Shaul
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

3.  Coupling of Fcγ receptor I to Fcγ receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function.

Authors:  Nathan C Sundgren; Weifei Zhu; Ivan S Yuhanna; Ken L Chambliss; Mohamed Ahmed; Keiji Tanigaki; Michihisa Umetani; Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2011-09-22       Impact factor: 17.367

4.  Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein.

Authors:  Xuguang Li; Guangtian Yang; Gang Zhao; Bin Wu; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  Hypertens Res       Date:  2011-05-12       Impact factor: 3.872

Review 5.  The role of nutrition and nutraceutical supplements in the treatment of hypertension.

Authors:  Mark Houston
Journal:  World J Cardiol       Date:  2014-02-26

6.  C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes.

Authors:  F Liu; H Y Chen; X R Huang; A C K Chung; L Zhou; P Fu; A J Szalai; H Y Lan
Journal:  Diabetologia       Date:  2011-07-09       Impact factor: 10.122

7.  Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats.

Authors:  Hongjing Guan; Peihua Wang; Rutai Hui; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  Clin Chem       Date:  2008-12-04       Impact factor: 8.327

8.  Adiponectin protects against incident hypertension independent of body fat distribution: observations from the Dallas Heart Study.

Authors:  Poghni A Peri-Okonny; Colby Ayers; Naim Maalouf; Sandeep R Das; James A de Lemos; Jarett D Berry; Aslan T Turer; Ian J Neeland; Philipp E Scherer; Wanpen Vongpatanasin
Journal:  Diabetes Metab Res Rev       Date:  2016-08-18       Impact factor: 4.876

9.  Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance.

Authors:  Ishwarlal Jialal; Subodh Verma; Sridevi Devaraj
Journal:  Clin Chem       Date:  2008-12-18       Impact factor: 8.327

10.  Proinflammation and hypertension: a population-based study.

Authors:  Vanhala Mauno; Kautiainen Hannu; Kumpusalo Esko
Journal:  Mediators Inflamm       Date:  2008-12-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.